Zealand Pharma AS (CHIX:ZEALC) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


CHIX:ZEALC Zealand Pharma AS CHIX:ZEALC
58 GF Score
Price kr278.70
GF Value kr12,477.77
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Zealand Pharma AS Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Zealand Pharma AS's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

CHIX:ZEALC vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Zealand Pharma AS's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zealand Pharma AS Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Zealand Pharma AS's Margin of Safety % (DCF Earnings Based) falls into.


CHIX:ZEALC
58GF Score
Zealand Pharma AS CHIX:ZEALC
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Zealand Pharma AS (CHIX:ZEALC) Overvalued in 2026?

Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued. The current stock price of kr278.70 is trading 97.8% below its estimated GF Value™ of kr12,477.77. GuruFocus considers Zealand Pharma AS to be Possible Value Trap.

Key valuation signals for CHIX:ZEALC:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: kr12,477.77 vs. price of kr278.70 (97.8% below fair value)
  • GF Score™: 58/100 with 3 warning signs

No single metric tells the full story. See the CHIX:ZEALC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zealand Pharma AS Business Description

Address Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
58GF Score

Get the complete analysis for CHIX:ZEALC

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr278.70
Price
kr12,477.77
GF Value